NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal

Madrigal Pharmaceuticals’ Rezdiffra is the first FDA-approved treatment for noncirrhotic non-alcoholic steatohepatitis, now referred to as metabolic dysfunction-associated steatohepatitis.